Galderma raises 2026 net sales growth forecast to 22.5%-23.5% at constant currency
Bitget2026/10/22 14:34- Galderma raised its 2026 net sales growth forecast to 22.5%-23.5% at constant currency from 19%-21%.
- Core EBITDA margin guidance remained approximately 26% at constant currency, despite growth investments.
- Nine-month net sales reached USD 4.77 billion, up 25.1% at constant currency, with volume the primary growth driver.
- The ZO Skin Health acquisition is expected to be neutral for core EPS in 2027, but slightly dilutive to core EBITDA.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
USD/JPY Price Forecast: Remains close to 20-day EMA
OpenAI president confirms IPO in 2027: enterprise clients have become the main source of revenue, but funding target has shrunk from 30 billions to 20 billions
OpenAI President Brockman stated that enterprise sales have contributed the majority of the company's revenue, and the company will be ready for an IPO by 2027. OpenAI is accelerating fundraising and competing with Anthropic, which is aiming to go public by the end of the year.
Former Citi executive Klein establishes another SPAC; Churchill Capital XIV (CXIVU.US) plans to raise up to $300 million in US IPO
Churchill Capital XIV filed an application with the SEC on Wednesday, seeking to raise up to $300 million through an initial public offering (IPO).
Evercore issues an investment guide for the "Blue Wave": AI infrastructure sentiment under pressure, names 5 "defensive" tech stocks.
Evercore stated that after the "blue wave," technology stocks such as Amphenol and Apple are worth holding.
Crypto prices
More
